Kyowa Kirin and Kura initiated a part II trial of ziftomenib for AML
Kyowa Kirin and Kura Oncology have initiated a Japanese part II registrational research of oral menin inhibitor ziftomenib in grownup sufferers with relapsed or refractory (r/r) NPM1-mutated acute myeloid leukemia (AML).
The one-arm, open-label, multicenter research will assess the efficacy and security of ziftomenib in these sufferers.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The first endpoint is the composite full remission price, which incorporates each full remission (CR) and full remission with partial hematologic restoration (CRh).
Kyowa Kirin plans to hunt regulatory approval in Japan upon completion of the trial.
Ziftomenib acquired U.S. Meals and Drug Administration (FDA) approval in November 2025, below the model title Komzifti, for adults with r/r NPM1 mutated AML who don’t have any passable various remedy choices.
Ziftomenib can be in improvement, together with customary of care and focused therapies for first-line AML with NPM1 mutations, lysine methyltransferase 2A (KMT2A) translocations, and FMS-like tyrosine kinase 3 (FLT3) mutations.
Kyowa Kirin Chief Medical Officer Yoshifumi Torii mentioned: “Sufferers with r/r NPM1-m AML usually face limitations of current remedy choices and have a important want for brand spanking new therapeutic options. Ziftomenib has the potential to offer a brand new remedy method for these sufferers.
“The initiation of this research is a part of Kyowa Kirin’s patient-focused drug improvement efforts in our precedence space of ’hematological malignancies and refractory hematological illnesses’.
“We are going to proceed this analysis as applicable and work onerous to verify efficacy and security, with the aim of finally offering a brand new remedy choice to deal with unmet wants of sufferers in Japan as shortly as potential.”
Final month, Kyowa Kirin introduced the worldwide halt of all ongoing scientific trials of rocatinlimab, an anti-OX40 monoclonal antibody being investigated for reasonable to extreme atopic dermatitis, prurigo nodularis and reasonable to extreme bronchial asthma.
